Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?

被引:10
|
作者
Kuang, Ze-Min [1 ]
机构
[1] Capital Med Univ, Dept Hypertens, Beijing Anzhen Hosp, Beijing 100029, Peoples R China
关键词
CARDIOVASCULAR RISK-FACTORS; SYSTOLIC BLOOD-PRESSURE; SERUM-CHOLESTEROL; STATIN USE; ALZHEIMERS-DISEASE; DEMENTIA; DECLINE; ASSOCIATION; MIDLIFE; HYPERTENSION;
D O I
10.1155/2020/1484357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive decline or development of dementia. To provide a reference for clinical treatment, we analyzed the potential mechanisms of cognitive dysfunction induced by hypertension and hyperlipidemia, the clinical research and controversy of antihypertensive and lipid-lowering therapies on cognitive function, and the clinical value of combined antihypertensive and lipid-lowering therapy. It is currently believed that hypertension and elevated blood cholesterol levels in middle-aged people may be related to cognitive impairment or dementia in the elderly. Some studies suggest that intensive antihypertensive or lipid-lowering therapies are better than standard antihypertensive or lipid-lowering therapy, yet further tests are needed to confirm their effects on cognitive function. Actively controlling potential risk factors from middle age may be important for Alzheimer's disease (AD) prevention.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Combined antihypertensive and lipid-lowering treatment
    Cesari, M
    Pessina, AC
    CURRENT HYPERTENSION REPORTS, 2004, 6 (04) : 300 - 306
  • [2] Combined antihypertensive and lipid-lowering treatment
    Maurizio Cesari
    Achille C. Pessina
    Current Hypertension Reports, 2004, 6 : 300 - 306
  • [3] Cardiovascular Pharmacogenetics of Antihypertensive and Lipid-Lowering Therapies
    Vanichakarn, P.
    Hwa, J.
    Stitham, J.
    CURRENT MOLECULAR MEDICINE, 2014, 14 (07) : 849 - 879
  • [4] COMBINED LIPID-LOWERING AND ANTIHYPERTENSIVE TREATMENT AS PART OF A STRATEGY OF MULTIPLE RISK FACTOR INTERVENTION
    MACDONALD, NJ
    FARISH, E
    STARK, S
    BARNES, JF
    ROLTON, H
    SABA, SN
    ELLIOTT, HL
    REID, JL
    JOURNAL OF HUMAN HYPERTENSION, 1991, 5 (05) : 449 - 454
  • [5] COMBINED ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY IN EXPERIMENTAL GLOMERULONEPHRITIS
    RUBIN, R
    SILBIGER, S
    SABLAY, L
    NEUGARTEN, J
    HYPERTENSION, 1994, 23 (01) : 92 - 95
  • [6] Synchronizing antihypertensive and lipid-lowering therapies increases patient adherence
    Agarwal, Shuchita
    Tang, Simon
    McLaughlin, Trent
    Joyce, Amie
    Schwartz, J. Sanford
    CIRCULATION, 2006, 113 (21) : E794 - E795
  • [7] What is new in lipid-lowering therapies in diabetes?
    Cheung, Yee-Ming
    O'Brien, Richard
    Ekinci, Elif I.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (12) : 1472 - 1480
  • [8] Lipid-lowering therapies in development
    Wierzbicki, AS
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) : 1405 - 1418
  • [9] Lipid-lowering Therapies in Myositis
    Marisa C. Mizus
    Eleni Tiniakou
    Current Rheumatology Reports, 2020, 22
  • [10] Lipid-lowering therapies in development
    Wierzbicki, A. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 465 - 465